• Vaccine Name: ID93 + GLA-SE
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: The antigen is ID93, which is a fusion protein made of 4 Mycobacterium tuberculosis antigens (Rv2608, Rv3619, Rv3620, Rv1813) (Day et al., 2021).
• Rv1813c gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Day et al., 2021).
    ID93 was generated through a tandem fusion of the individual cloned and amplified genes of Rv3619, Rv1813, Rv3620, and Rv2608 using restriction site linkers.(Bertholet et al., 2010)
  • Detailed Gene Information: Click Here.
• PPE42 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Day et al., 2021).
    ID93 was generated through a tandem fusion of the individual cloned and amplified genes of Rv3619, Rv1813, Rv3620, and Rv2608 using restriction site linkers.(Bertholet et al., 2010)
  • Detailed Gene Information: Click Here.
• esxW gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Day et al., 2021).
    ID93 was generated through a tandem fusion of the individual cloned and amplified genes of Rv3619, Rv1813, Rv3620, and Rv2608 using restriction site linkers.(Bertholet et al., 2010)
  • Detailed Gene Information: Click Here.
• esxV gene engineering:
  • Type: Fusion Protein
  • Description: This is use for fusion protein preparation (Day et al., 2021).
    ID93 was generated through a tandem fusion of the individual cloned and amplified genes of Rv3619, Rv1813, Rv3620, and Rv2608 using restriction site linkers.(Bertholet et al., 2010)
  • Detailed Gene Information: Click Here.
• Adjuvant: GLA-SE vaccine adjuvant
  • Adjuvant name: GLA-SE vaccine adjuvant
  • VO adjuvant ID: VO_0005420
  • Description: GLA-SE adjuvant is use to enhances Th1 and IFN-? immune responses (Day et al., 2021).
• Preparation: The recombinant ID93 fusion protein is expressed and purified, then mixed with the GLA-SE adjuvant (oil-in-water emulsion containing a TLR4 agonist) to create the final injectable vaccine formulation (Day et al., 2021).
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccination Protocol: Participants received intramuscular injections of ID93 + GLA-SE on day 0 and day 56, with some groups receiving an additional dose on day 28 (prime–boost or 3-dose schedule depending on cohort) (Day et al., 2021).
• Immune Response: Vaccination generated strong antigen-specific IgG antibody responses and polyfunctional CD4? T-cell responses that were durable and significantly higher than placebo (Day et al., 2021).